A share price of Acadia Pharmaceuticals Inc [ACAD] is currently trading at $17.28, up 3.41%. An important factor to consider is whether the stock is rising or falling in short-term value. The ACAD shares have gain 5.88% over the last week, with a monthly amount glided 9.44%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Morgan Stanley downgraded its rating to Equal-Weight on August 07, 2024, and dropped its price target to $20. On June 27, 2024, BMO Capital Markets initiated with a Outperform rating and assigned a price target of $31 on the stock. Needham reiterated its Buy rating and decreased its price target to $32 on March 12, 2024. Mizuho downgraded its rating to a Neutral and reduced its price target to $25 on March 12, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on January 30, 2024, and assigned it a price target of $40. In a note dated January 24, 2024, Needham upgraded an Buy rating on this stock but restated the target price of $37.
Acadia Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $14.15 and $32.59. Currently, Wall Street analysts expect the stock to reach $25.5 within the next 12 months. Acadia Pharmaceuticals Inc [NASDAQ: ACAD] shares were valued at $17.28 at the most recent close of the market. An investor can expect a potential return of 47.57% based on the average ACAD price forecast.
Analyzing the ACAD fundamentals
Trailing Twelve Months sales for Acadia Pharmaceuticals Inc [NASDAQ:ACAD] were 929.24M which represents 18.28% growth. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at 0.12%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.13, Equity is 0.26 and Total Capital is 0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.89 points at the first support level, and at 16.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 17.52, and for the 2nd resistance point, it is at 17.75.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Acadia Pharmaceuticals Inc [NASDAQ:ACAD] is 2.29. On the other hand, the Quick Ratio is 2.11, and the Cash Ratio is 0.45. Considering the valuation of this stock, the price to sales ratio is 3.20, the price to book ratio is 4.98 and price to earnings (TTM) ratio is 22.37.
Transactions by insiders
Recent insider trading involved Teehan Brendan, EVP, COO, HEAD OF COMMERCIAL, that happened on Nov 19 ’24 when 10329.0 shares were sold. PRINCIPAL ACCOUNTING OFFICER, Kihara James completed a deal on Nov 19 ’24 to sell 4073.0 shares. Meanwhile, EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. sold 10259.0 shares on Nov 19 ’24.
